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ABSTRACT 
BCL2 EXPRESSION IN BREAST CARCINOMA  AND ITS ASSOCIATION WITH 
OTHER CLINICOPATHOLOGIC FACTORS 
BACKGROUND 
        Anti Apoptotic marker(Bcl2) can be a new advance front in the assessment of prognosis 
of breast cancer. Apoptotic and Antiapoptotic proteins along with other proteins involved in 
cell proliferation and control plays a complex role in the etiopathogenesis of breast cancer. 
AIM 
      Our aim is to study the Bcl2 expression in breast carcinoma and its association with other 
clinicopathologic factors such as tumour size,lymphnode status,ER/PR ,Her2 
expression,histologic grade and Nottingham prognostic index 
MATERIALS AND METHODS 
    30 cases of breast carcinoma including IDC-NOS type and some special histologic 
subtypes are randomly selected and representative sections are taken.Immunohistochemistry  
for Bcl2,ER,PR,Her2/neu was done.Bcl2 expression in those cases are observed,statistically 
analysed and compared with other clinicopathologic factors such as tumour size,lymphnode 
status,ER/PR,Her2/neu expression and Nottingham prognostic index 
RESULTS 
        7 out of 30 cases( 23.3 %) shows positivity for Bcl2,all of them show strong cytoplasmic 
positivity. Bcl2 positive cases(7/7) were positive for both ER and PR(p value<0.004 
significant).But none of the Bcl2 positive cases shows immunoexpression for Her2/neu.Bcl2 
positive cases shows statistically significant correlation with lower histologic grade (p value-
< 0.006 ) in ductal carcinoma NS type and all mucinous carcinoma(p value<0.025), small 
tumour size(p value<0.024) in ductal carcinoma NS type.It doesn’t correlation with 
lymphnode  
CONCLUSION 
       To conclude that,Bcl2 expression in invasive ductal carcinoma is directly 
correlated with lower histologic grade(well differentiated tumours),small tumour 
size,ER+,PR+ Status of individual,all cases of mucinous carcinoma of breast.It inversely 
correlated with  Her2/neu status,other special histologic subtypes(metaplastic and secretory 
carcinoma). 
 These data promises on a new approach to enhance the efficacy  of endocrine treatment in 
estrogen receptor-positive (ER+) breast cancer by negating the  antiapoptotic effect of BCL-2 
by using  BH3 mimetics 
  
